Switching from ranibizumab to aflibercept for eye conditions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effects of switching patients with recurrent or persistent neovascular age-related macular degeneration (nAMD) and diabetic retinopathy from ranibizumab therapy to aflibercept. It includes 20 patients aged 50 and older who have been treated with ranibizumab for up to one year. Participants will undergo monthly examinations over a 12-month follow-up period to assess visual acuity and other ophthalmic parameters. The goal is to determine the efficacy of aflibercept in improving visual outcomes in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adults ≥ 50 years

* Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year
* BCVA \>= 20/400 in the study eye using ETDRS
* Willingness and ability to comply with regular visits
* Signed informed consent

Exclusion Criteria:

* Any surgical treatment of the eye within 3 months prior to baseline in the study eye
* History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
* Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye
* Retinal pigment epithelial tear involving the macula in the study eye

Where it's running

• Medical University of Vienna
  Vienna, Austria Recruiting

Study contacts

• Study coordinator: Reinhard Told, MD, PhD
• Email: reinhard.told@meduniwien.ac.at
• Phone: +43140400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• Switching patients with AMD from ranibizumab or aflibercept to faricimab

  This study is testing if switching people with age-related macular degeneration from their current eye injections to a new treatment called faricimab can improve their vision and reduce the number of injections they need.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT06271330

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

• SMZ1 plus ranibizumab vs placebo plus ranibizumab for wet AMD without PCV

  A study tests whether SMZ1 tablets added to ranibizumab can give better vision improvement than placebo with ranibizumab in people 50 and older with a specific form of wet age-related macular degeneration.

  Recruiting Phase 3 SANGMYUNG innovation · Seoul, Seoul · NCT07695207

• First-in-human test of ARO-033 in adults

  This study tests whether ARO-033 is safe and tolerable, and how it behaves in the body, in healthy adults and in adults with age-related macular degeneration.

  Recruiting Phase 1 Arrowhead Pharmaceuticals · Auckland · NCT07662096

• Predicting Risk of AMD Progression Using Imaging in Aging Eyes

  Researchers are test a new screening approach to detect early AMD and monitor its progression in adults 55 and older, to see if personalized monitoring can help in community settings.

  Recruiting at 2 sites Singapore National Eye Centre · Singapore and 1 other locations · NCT07653269

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.